Cleveland Clinic Cancer Advances
Health & Fitness
Trailblazing Urothelial Cancer Treatments: Enfortumab Vedotin & Pembrolizumab
Shilpa Gupta, MD, Director of the Genitourinary Oncology Program at Cleveland Clinic Cancer Institute, provides an overview of the clinical trial of enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. Listen as Dr. Gupta talks about the exciting results of the trial, which showed that the combination therapy was effective for both cisplatin-eligible and cisplatin-ineligible patients. She also highlights the future studies that are being conducted to explore the use of the therapy in the neoadjuvant setting.
Create your
podcast in
minutes
It is Free